2024
Rare presentations of glioblastoma multiforme in the septum pellucidum: illustrative case
Subah G, Zeller S, Jain A, Gozum N, Smith G, Cooper J, Kleinman G, Gandhi C, Hanft S. Rare presentations of glioblastoma multiforme in the septum pellucidum: illustrative case. Journal Of Neurosurgery Case Lessons 2024, 8: case23770. PMID: 39432918, PMCID: PMC11505928, DOI: 10.3171/case23770.Peer-Reviewed Original ResearchGlioblastoma multiformeSeptum pellucidumInitial head computed tomographyHistory of prostate carcinomaKi-67 labeling indexHigh-grade primary brain tumorsTumor grade 4Head Computed TomographyDiverse clinical presentationsPrimary brain tumorGlial fibrillary acidic proteinFibrillary acidic proteinMagnetic resonance imagingProstate carcinomaBiopsy findingsRare presentationIntracranial malignanciesClinical presentationKi-67Mass lesionDiagnostic advancesLabeling indexLateral ventricleNeuro-oncologyInfiltrative growthPhase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
Gettinger S, Song Z, Reckamp K, Moscow J, Gray R, Wang V, McShane L, Rubinstein L, Patton D, Williams P, Hamilton S, Kong X, Tricoli J, Conley B, Arteaga C, Harris L, O'Dwyer P, Chen A, Flaherty K. Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A. JCO Precision Oncology 2024, 8: e2300725. PMID: 38986051, DOI: 10.1200/po.23.00725.Peer-Reviewed Original ResearchConceptsProgression-free survivalTyrosine kinase inhibitorsEGFR tyrosine kinase inhibitorsNCI-MATCHLung cancerGlioblastoma multiformeOverall survivalAdvanced non-small cell lung cancerNational Cancer Institute-Molecular AnalysisNon-small cell lung cancerEnd pointsTumor genomic testingTrial primary end pointPhase 2 trialPhase II trialSecondary end pointsPrimary end pointCell lung cancerCohort of patientsMedian OSStable diseaseAdenosquamous carcinomaProtocol therapyPartial responseArm AStructural insights into the role and targeting of EGFRvIII
Bagchi A, Stayrook S, Xenaki K, Starbird C, Doulkeridou S, El Khoulati R, Roovers R, Schmitz K, van Bergen En Henegouwen P, Ferguson K. Structural insights into the role and targeting of EGFRvIII. Structure 2024, 32: 1367-1380.e6. PMID: 38908376, PMCID: PMC11380598, DOI: 10.1016/j.str.2024.05.018.Peer-Reviewed Original ResearchAutocatalytic, Brain Tumor‐Targeting Delivery of Bardoxolone Methyl Self‐Assembled Nanoparticles for Glioblastoma Treatment
Ye Z, Sheu W, Qu H, Peng B, Liu J, Zhang L, Yuan F, Wei Y, Zhou J, Chen Q, Xiao X, Zhang S. Autocatalytic, Brain Tumor‐Targeting Delivery of Bardoxolone Methyl Self‐Assembled Nanoparticles for Glioblastoma Treatment. Small Science 2024, 4: 2400081. PMID: 40212541, PMCID: PMC11935168, DOI: 10.1002/smsc.202400081.Peer-Reviewed Original ResearchBlood-brain barrierBardoxolone methylGlioblastoma multiformeBrain tumorsSurvival of miceSelf-assembled nanoparticlesInhibited GBM tumor growthEnhance drug penetrationGlioblastoma multiforme treatmentKill GBM cellsLack of effective drugsTumor growthDrug penetrationIntravenous administrationP28 peptideEffective drugsGlioblastoma treatmentTumorClinical applicationGBM cellsPeptide-conjugatesTreatmentBrainBardoxoloneGlioblastoma
2022
Pneumocystis jirovecii pneumonia and deep vein thrombosis in a patient with glioblastoma multiforme
Hussain H, Paidas M, Fadel A, Garcia E, Saadoon Z, Mendez L, Jayakumar A. Pneumocystis jirovecii pneumonia and deep vein thrombosis in a patient with glioblastoma multiforme. Discoveries 2022, 10: e161. PMID: 37457643, PMCID: PMC10338259, DOI: 10.15190/d.2022.20.Peer-Reviewed Original ResearchDeep vein thrombosisPneumocystis jirovecii pneumoniaPneumocystis jirovecii pneumonia infectionAcute deep vein thrombosisJirovecii pneumoniaVein thrombosisPneumonia infectionGlioblastoma multiformeBilateral lower extremity swellingGround glass changesLower extremity swellingChest X-rayPolymerase chain reaction testChain reaction testPulmonary infectionExtremity swellingBronchoalveolar lavageClinical featuresInterstitial infiltratesAtypical infectionsEmergency departmentMedical historyFurther managementSulfamethoxazole treatmentDoppler ultrasoundDelayed, Progressive Multivessel Occlusion After Resection of a Recurrent Glioma
Tanglay O, Dadario N, Young I, Yeung J, Teo C, Sughrue M, Yeung J. Delayed, Progressive Multivessel Occlusion After Resection of a Recurrent Glioma. Cureus 2022, 14: e33019. PMID: 36721529, PMCID: PMC9879796, DOI: 10.7759/cureus.33019.Peer-Reviewed Original ResearchMagnetic resonance imagingCerebral artery infarctionArtery infarctionGlioma resectionGlioblastoma multiformeMiddle cerebral artery infarctionPreoperative magnetic resonance imagingCommon primary brain tumorPosterior cerebral artery infarctionAggressive cytoreductive surgeryAggressive natural historyMiddle cerebral arteryPrimary brain tumorsMost clinical researchMultivessel occlusionCytoreductive surgeryAdjuvant radiochemotherapyMedian survivalNeurologic declineOverall survivalTotal resectionVascular etiologyCerebral arteryPatient outcomesClinical guidanceSingle brain metastasis versus glioblastoma multiforme: a VOI-based multiparametric analysis for differential diagnosis
Romano A, Moltoni G, Guarnera A, Pasquini L, Di Napoli A, Napolitano A, Espagnet M, Bozzao A. Single brain metastasis versus glioblastoma multiforme: a VOI-based multiparametric analysis for differential diagnosis. La Radiologia Medica 2022, 127: 490-497. PMID: 35316518, PMCID: PMC9098536, DOI: 10.1007/s11547-022-01480-x.Peer-Reviewed Original ResearchConceptsArea under the curveReceiver Operating CharacteristicSolitary BMBrain metastasesDifferential diagnosisPerfusion curvesMultiparametric MRI modelValues of rCBVSingle brain metastasisSolitary brain metastasisMethodsForty-one patientsReceiver operating characteristic analysisEnhancing tumorValues of ADCResidual edemaRCBV valuesPeritumoral edemaPerilesional edemaTwo-sample t-testMethodsForty-oneCerebral edemaBM groupGlioblastoma multiformeEdemaROC curve
2021
Current Advances in Immunotherapy for Glioblastoma Multiforme and Future Prospects
Chowdhury S, Bappy M, Clocchiatti-Tuozzo S, Cheeti S, Chowdhury S, Patel V. Current Advances in Immunotherapy for Glioblastoma Multiforme and Future Prospects. Cureus 2021, 13: e20604. PMID: 35103180, PMCID: PMC8782638, DOI: 10.7759/cureus.20604.Peer-Reviewed Original ResearchChimeric antigen receptorAdoptive cell transferGlioblastoma multiformeOncolytic virusesNanomedicine-based immunotherapyImmune-targeted therapiesResistant to current treatmentsMalignant type of brain tumorClinical trial outcomesImmunosuppressive tumorsCancer vaccinesImmunotherapy approachesImmune microenvironmentT cellsAntigen receptorCell transferImmune targetsImmunotherapyMalignant typeCurrent treatmentBrain tumorsType of brain tumorGlioblastomaClinical standpointDisease biologyA Deep Dive: SIWV Tetra-Peptide Enhancing the Penetration of Nanotherapeutics into the Glioblastoma
Kang R, Park J, Kim J, Chowdhury T, Oh J, Kim J, Shin J, Kim M, Park C, Lee S, Lee J, Kim D. A Deep Dive: SIWV Tetra-Peptide Enhancing the Penetration of Nanotherapeutics into the Glioblastoma. ACS Biomaterials Science & Engineering 2021, 8: 4163-4174. PMID: 34196517, DOI: 10.1021/acsbiomaterials.1c00653.Peer-Reviewed Original ResearchConceptsDrug delivery systemsNanoparticle-based drug delivery systemsPolyethylene glycolHigher anticancer efficacyPorous silicon nanoparticlesDevelopment of nanotherapeuticsGlioblastoma multiformeSilicon nanoparticlesTetra peptideIRGD peptideTargeting abilityDelivery systemAnticancer efficacyNanoparticlesTherapeutic formulationsGreat promiseAggressive malignant tumorSite targetingNanotherapeuticsCell spheroidsPenetration abilityStructure specificityMalignant tumorsPenetration depthXenograft miceBrain Tumor Reporting and Data System: A Pictorial Review
Rao B, Ikuta I, Mahajan A, Karam A, Zohrabian V. Brain Tumor Reporting and Data System: A Pictorial Review. Neurographics 2021, 11: 175-185. DOI: 10.3174/ng.2000069.Peer-Reviewed Original ResearchBrain Tumor ReportingBrain tumorsBT-RADSTiming of therapyMalignant brain tumorsMR imaging featuresGrade IV gliomasPictorial review articleMost common formsSubstantial morbidityCNS tumorsPoor prognosisImaging featuresClinical assessmentNeurologic specialistPictorial reviewGlioblastoma multiformeNew classification systemPrimary gliomasTumorsData SystemCommon formRadiologic reportingTherapyGliomasProgesterone Modulates Mitochondrial Functions in Human Glioblastoma Cells
Atif F, Yousuf S, Espinosa-Garcia C, Stein D. Progesterone Modulates Mitochondrial Functions in Human Glioblastoma Cells. Molecular Neurobiology 2021, 58: 3805-3816. PMID: 33847913, DOI: 10.1007/s12035-021-02382-1.Peer-Reviewed Original ResearchConceptsExtracellular acidification rateEffects of P4Glioblastoma multiformeGlioblastoma multiforme cell linesGlioblastoma multiforme cellsCell linesInhibitory effectDecreased tumor sizeSuperoxide radical generationMitochondrial functionDose-dependent inhibitory effectOxygen consumption rateTime-response studiesMitochondrial respirationHuman glioblastoma multiformeMitochondrial stress testSpread of glioblastoma multiformeCompared to controlsTumor sizeConcentrations of P4Human glioblastoma cellsModulate mitochondrial functionNonmitochondrial oxygen consumptionMaximum inhibitory effectDose responseDeep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM
Pasquini L, Napolitano A, Tagliente E, Dellepiane F, Lucignani M, Vidiri A, Ranazzi G, Stoppacciaro A, Moltoni G, Nicolai M, Romano A, Di Napoli A, Bozzao A. Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM. Journal Of Personalized Medicine 2021, 11: 290. PMID: 33918828, PMCID: PMC8069494, DOI: 10.3390/jpm11040290.Peer-Reviewed Original ResearchConvolutional neural networkCategorical cross-entropy lossDeep learning modelsDeep learningMagnetic resonance imagingCross-entropy lossMagnetic resonance imaging sequencesGlioblastoma multiformeNeural networkActivation functionMultiparametric magnetic resonance imagingWHO grade IV gliomasGrade IV gliomasMaximal accuracyIDH testingIDH-wildRCBV mapsIDH mutationsIV gliomasDiagnostic challengeAdult patientsGlioma populationIDH-mutantADC mapsHypoxia-inducible factor
2020
Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma
Auer TA, Della Seta M, Collettini F, Chapiro J, Zschaeck S, Ghadjar P, Badakhshi H, Florange J, Hamm B, Budach V, Kaul D. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma. Acta Radiologica 2020, 62: 1200-1207. PMID: 32938221, DOI: 10.1177/0284185120953796.Peer-Reviewed Original ResearchConceptsProgression-free survivalOverall survivalTumor volumeGlioblastoma multiformeMagnetic resonance imagingMultivariable analysisCommon malignant primary brain tumorIntracranial progression-free survivalKarnofsky performance status scoreCranial magnetic resonance imagingMalignant primary brain tumorMedian overall survivalPerformance status scoreOS of patientsCox regression modelSignificant prognostic rolePrimary brain tumorsContrast-enhanced MRI sequencesQuantitative volumetric assessmentResection statusPrognostic roleMethyltransferase statusWorse prognosisEntire cohortNon-invasive methodDifferential expression of the T-cell inhibitor TIGIT in glioblastoma and MS
Lucca LE, Lerner BA, Park C, DeBartolo D, Harnett B, Kumar VP, Ponath G, Raddassi K, Huttner A, Hafler DA, Pitt D. Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS. Neurology Neuroimmunology & Neuroinflammation 2020, 7: e712. PMID: 32269065, PMCID: PMC7188477, DOI: 10.1212/nxi.0000000000000712.Peer-Reviewed Original ResearchConceptsTumor-infiltrating T cellsT cellsPD-1/PD-L1Anti-TIGIT therapyExpression of CD226Expression of TIGITPostmortem CNS tissueLymphocytes of patientsFresh surgical resectionsLigand CD155TIGIT expressionSurgical resectionPD-1PD-L1CNS diseaseHealthy controlsHealthy donorsLymphocytic expressionImmune responseCNS tissueMS lesionsTIGITImmune pathwaysPatientsGlioblastoma multiforme
2018
ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION
Antonios J, Everson R, Soto H, Khattab S, Bethel J, Sun M, Mochizuki A, Lee A, Odesa S, Billingslea-Yoon E, Moughon D, Wang A, Cloughesy T, Prins R, Liau L. ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION. Neuro-Oncology 2018, 20: vi10-vi10. PMCID: PMC6216157, DOI: 10.1093/neuonc/noy148.034.Peer-Reviewed Original ResearchToll-like receptorsMedian survivalDendritic cellsDC vaccinesGrade III or IV gliomaTumor lysate-pulsed DCGlioblastoma multiformePoly ICLCAutologous tumor lysateDC vaccine treatmentLysate-pulsed DCMGMT methylated tumorsMGMT unmethylated tumorsTLR-7 agonistPeripheral blood mononuclear cellsGrade III tumorsTLR-3 agonistIncreased overall survivalGrade IV tumorsBlood mononuclear cellsModulate immune responsesIII tumorsIV tumorsMethylated tumorsOverall survival
2017
Usefulness of enhancement-perfusion mismatch in differentiation of CNS lymphomas from other enhancing malignant tumors of the brain
Goyal P, Kumar Y, Gupta N, Malhotra A, Gupta S, Gupta S, Mangla M, Mangla R. Usefulness of enhancement-perfusion mismatch in differentiation of CNS lymphomas from other enhancing malignant tumors of the brain. Quantitative Imaging In Medicine And Surgery 2017, 7: 511-519. PMID: 29184763, PMCID: PMC5682400, DOI: 10.21037/qims.2017.09.03.Peer-Reviewed Original ResearchCNS lymphomaGlioblastoma multiformeMalignant lesionsMean rCBVSecondary central nervous system lymphomaCentral nervous system lymphomaDifferentiation of CNSMagnetic resonance perfusion imagingNervous system lymphomaRelative cerebral blood volumePerfusion imagesDSC perfusion MRCerebral blood volumeRelative CBV valuesMann-Whitney testEnhancing partSystem lymphomaLymphoma patientsTreatment optionsAnaplastic gliomasTumor differentiationMalignant tumorsPerfusion MRGlioma patientsBlood volumeFunctional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme
Goods BA, Hernandez AL, Lowther DE, Lucca LE, Lerner BA, Gunel M, Raddassi K, Coric V, Hafler DA, Love JC. Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme. PLOS ONE 2017, 12: e0181538. PMID: 28880903, PMCID: PMC5589094, DOI: 10.1371/journal.pone.0181538.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPD-1 expressionEffector T cellsPD-1Effector cellsGlioblastoma multiformeCheckpoint inhibitorsTim-3T cellsHealthy subjectsCell death protein 1Features of exhaustionDeath protein 1T cell compartmentContext of GBMRecovery of functionCD4 effectorsCD4 cellsRNA sequencingTreatment of cancerHealthy donorsGBM patientsBrain cancerCD4TumorsO6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors
Raj N, Klimstra D, Horvat N, Zhang L, Chou J, Capanu M, Basturk O, Gian R, Allen P, Reidy-Lagunes D. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. Pancreas 2017, 46: 758-763. PMID: 28609363, PMCID: PMC5509357, DOI: 10.1097/mpa.0000000000000842.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic Agents, AlkylatingBiomarkers, TumorCell DifferentiationChildDacarbazineDatabases, FactualDisease ProgressionDNA MethylationDNA Modification MethylasesDNA Repair EnzymesDrug Resistance, NeoplasmFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedNeoplasm GradingNeuroendocrine TumorsPancreatic NeoplasmsPharmacogeneticsPromoter Regions, GeneticSequence Analysis, DNATemozolomideTime FactorsTreatment OutcomeTumor Suppressor ProteinsYoung AdultConceptsPancreatic neuroendocrine tumorsProgression of diseaseWD-panNETsStable diseasePartial responseNeuroendocrine tumorsAlkylating agentsAlkylating agent therapyResponse Evaluation CriteriaResistance to alkylating agentsMGMT deficiencyAgent therapyEvaluation CriteriaSolid tumorsMGMTTumorGlioblastoma multiformePanNETsPatientsDiseaseDecreased activityDNA methyltransferasesAgentsRECISTStatusEpithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme
Qin Y, Takahashi M, Sheets K, Soto H, Tsui J, Pelargos P, Antonios J, Kasahara N, Yang I, Prins R, Braun J, Gordon L, Wadehra M. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. Journal Of Neuro-Oncology 2017, 134: 29-40. PMID: 28597184, PMCID: PMC5695892, DOI: 10.1007/s11060-017-2507-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, CD34Cell Line, TumorCell MovementFemaleGene Expression Regulation, NeoplasticGlioblastomaGreen Fluorescent ProteinsHuman Umbilical Vein Endothelial CellsHumansImmunoglobulin GMembrane GlycoproteinsMiceMice, NudeMicroarray AnalysisNeovascularization, PathologicRNA, Small InterferingTransfectionVascular Endothelial Growth Factor AXenograft Model Antitumor AssaysConceptsExpression of epithelial membrane protein-2Anti-angiogenic therapyEpithelial membrane protein-2Glioblastoma multiformeSurvival benefitAnti-vascular endothelial growth factor AProgression-free survival benefitReduction of tumor loadDecreased tumor vasculatureRecurrent glioblastoma multiformeVEGF-A levelsEndothelial growth factor AAbnormal blood vesselsProtein 2Malignant brain tumorsAggressive malignant brain tumorGrowth factor AHuman glioblastoma multiformePotential therapeutic effectsTumor loadTumor expressionPro-angiogenic effectsTumor vasculatureClinical prognosisVEGF-AResveratrol Impairs Glioma Stem Cells Proliferation and Motility by Modulating the Wnt Signaling Pathway
Cilibrasi C, Riva G, Romano G, Cadamuro M, Bazzoni R, Butta V, Paoletta L, Dalprà L, Strazzabosco M, Lavitrano M, Giovannoni R, Bentivegna A. Resveratrol Impairs Glioma Stem Cells Proliferation and Motility by Modulating the Wnt Signaling Pathway. PLOS ONE 2017, 12: e0169854. PMID: 28081224, PMCID: PMC5231344, DOI: 10.1371/journal.pone.0169854.Peer-Reviewed Original ResearchConceptsGlioma stem cellsGlioblastoma multiformeResveratrol exposureSolid tumorsPleiotropic health benefitsProtein levelsHigh recurrence rateMalignant brain tumorsBetter therapeutic strategiesCell proliferationEpithelial-mesenchymal transition (EMT) programGrade IV astrocytomaGSC linesInteresting therapeutic approachWnt Signaling PathwayMedian survivalRecurrence rateGlioma stem cell proliferationCurrent therapiesPathway-related genesPolyphenolic phytoalexinGBM patientsTherapeutic approachesTherapeutic strategiesBrain tumors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply